Search
164 studies match these filters. Showing 51–75 of 164 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT07284979 | Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight. ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 59 sites in total | Recruiting | Phase 3 | 1,200target | 59 / 5 | 2025 | Sep 1, 2026 | |
| NCT07564414 | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eith… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 303 sites in total | Recruiting | Phase 3 | 2,500target | 303 / 19 | 2026 | Aug 31, 2026 | |
| NCT07662044 | A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucos… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 149 sites in total | Recruiting | Phase 3 | 800target | 149 / 13 | 2026 | Aug 31, 2026 | |
| NCT06319820 | A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 193 sites in total | Recruiting | Phase 3 | 641target | 193 / 20 | 2024 | Aug 28, 2026 | |
| NCT06662786 | A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folini… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 239 sites in total | Recruiting | Phase 3 | 1,000target | 239 / 22 | 2024 | Aug 28, 2026 | |
| NCT06750094 | A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovor… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 251 sites in total | Recruiting | Phase 3 | 700target | 251 / 26 | 2024 | Aug 28, 2026 | |
| NCT07196722 | A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 370 sites in total | Recruiting | Phase 2 / Phase 3 | 1,092target | 370 / 28 | 2025 | Aug 28, 2026 | |
| NCT07225946 | A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxe… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 152 sites in total | Recruiting | Phase 3 | 800target | 152 / 17 | 2025 | Aug 28, 2026 | |
| NCT07674654 | A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 113 sites in total | Recruiting | Phase 3 | 1,000target | 113 / 1 | 2026 | Aug 27, 2026 | |
| NCT06059638 | BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure pacemaker. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 131 sites in total | Recruiting | Not applicable | 316target | 131 / 15 | 2023 | Aug 26, 2026 | |
| NCT06742723 | A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 771 sites in total | Recruiting | Phase 3 | 5,000target | 771 / 42 | 2025 | Aug 26, 2026 | |
| NCT06283966 | A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 921 sites in total | Recruiting | Phase 3 | 5,000target | 921 / 37 | 2024 | Aug 26, 2026 | |
| NCT05102019 | Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coro… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 96 sites in total | Recruiting | Not applicable | 380target | 96 / 3 | 2022 | Aug 26, 2026 | |
| NCT07226791 | Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair A ventral hernia happens when the muscles in the front of your belly become weak and let organs push through, causing a bulge. If it gets worse, intestines can slip into the bulge, leading to serious pain and health problems. This study aims to asses if AGN-151607-DP is safe and effective for closin… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 13 sites in total | Recruiting | Phase 2 | 200target | 13 / 1 | 2026 | Aug 25, 2026 | |
| NCT07466316 | A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) This phase III trial compares higher dose chemotherapy, with vincristine, dactinomycin and cyclophosphamide, over a shorter amount of time to lower dose chemotherapy plus maintenance, with vincristine, dactinomycin, cyclophosphamide, irinotecan and vinorelbine, over a longer amount of time, along wi… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 87 sites in total · contact listed | Recruiting | Phase 3 | 342target | 87 / 2 | 2026 | Aug 25, 2026 | |
| NCT05677100 | Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 50 sites in total | Recruiting | Not applicable | 320target | 50 / 2 | 2023 | Aug 25, 2026 | |
| NCT07000357 | A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs pl… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 1,452 sites in total | Recruiting | Phase 3 | 15,100target | 1,452 / 36 | 2025 | Aug 24, 2026 | |
| NCT06424288 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empag… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 652 sites in total · contact listed | Recruiting | Phase 3 | 6,000target | 652 / 30 | 2024 | Aug 21, 2026 | |
| NCT07136012 | OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]). ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 252 sites in total | Recruiting | Phase 3 | 11,000target | 252 / 3 | 2025 | Aug 21, 2026 | |
| NCT07645924 | A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 113 sites in total · contact listed | Recruiting | Phase 3 | 1,800target | 113 / 1 | 2026 | Aug 20, 2026 | |
| NCT07415031 | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorect… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 100 sites in total · contact listed | Recruiting | Phase 2 | 170target | 100 / 20 | 2026 | Aug 18, 2026 | |
| NCT07097142 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine or mitomycin and 5-fluorouracil for the treatment of patients… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 211 sites in total · contact listed | Recruiting | Phase 3 | 486target | 211 / 1 | 2025 | Aug 18, 2026 | |
| NCT07567001 | A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to fi… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 838 sites in total | Recruiting | Phase 3 | 5,610target | 838 / 27 | 2026 | Aug 18, 2026 | |
| NCT05624996 | Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or targeted therapy with osimertinib) versus the usual treatment alone… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 477 sites in total · contact listed | Recruiting | Phase 3 | 474target | 477 / 2 | 2023 | Aug 17, 2026 | |
| NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnos… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 124 sites in total | Recruiting | Phase 3 | 750target | 124 / 15 | 2026 | Aug 14, 2026 |